Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Toshiki Yamada, Michio Sawada, Hideko Goto, Kenji Fukuno, Jun Ichi Kitagawa, Ichiro Yasuda, Naoki Katsumura, Masao Takemura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Introduction: We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). Here, we investigated whether the role of sFas as a prognostic factor remains valid in the R-CHOP era. Patients: We treated 132 patients with DLBCL between October 1995 and September 2002 (group A: without rituximab), and 75 between December 2002 and March 2007 (group B: with rituximab). The patients received eight cycles of CHOP or THP (tetrahydropyranyl-adriamycin)-COP before September 2002, and R-CHOP or R-THP-COP after October 2002. The distribution of patients according to the International Prognostic Index did not significantly differ between the groups. Results: The 5-year overall survival (OS) rates for patients with sFas levels of ≥3.0 and <3.0 ng/ml in group A were 19.8 and 61.9% (P < 0.0001), whereas the 3-year OS rates in group B were 54.7 and 92.2% (P < 0.01), respectively. Multivariate analysis using the proportional hazards model revealed that sFas most significantly correlated with overall survival (P < 0.05). Conclusion: Serum sFas is thus a useful tool for selecting the appropriate therapeutic strategy for DLBCL.

Original languageEnglish
Pages (from-to)1421-1428
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume135
Issue number10
DOIs
Publication statusPublished - 10-2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP'. Together they form a unique fingerprint.

Cite this